ATI RN
ATI RN Pharmacology 2023 V Questions
Extract:
Question 1 of 5
A nurse is preparing to administer a scheduled dose of warfarin to a client. Which of the following laboratory tests should the nurse review prior to administration?
Correct Answer: D
Rationale: The correct answer is D: PT (Prothrombin Time). Prothrombin Time measures the clotting ability of the blood, which is crucial for monitoring warfarin therapy. Warfarin is an anticoagulant that works by inhibiting clotting factors dependent on Vitamin K, such as prothrombin. By reviewing the PT before administering warfarin, the nurse can ensure the client's blood is clotting appropriately.
A: PTT (Partial Thromboplastin Time) measures the intrinsic pathway of the clotting cascade and is not specific to warfarin therapy.
B:
Total iron-binding capacity is unrelated to warfarin therapy.
C: WBC (White Blood Cell count) is not necessary to review before administering warfarin.
Question 2 of 5
A nurse is planning to administer a controlled substance to a client who is experiencing pain. Which of the following actions should the nurse plan to take first?
Correct Answer: B
Rationale: The correct answer is B: Identify the client using two identifiers. This step is crucial for patient safety and medication administration accuracy. By confirming the client's identity using two identifiers (name, date of birth, or medical record number), the nurse ensures the right medication is given to the right patient. This initial verification step helps prevent medication errors and ensures the client's safety. Removing the medication from the cabinet, documenting administration, and comparing medication amounts are important steps but should follow the crucial step of confirming the client's identity to minimize the risk of error.
Question 3 of 5
A nurse is reviewing the laboratory data of a client who is receiving filgrastim. Which of the following laboratory values should the nurse monitor to evaluate the effectiveness of the treatment?
Correct Answer: B
Rationale: The correct answer is B: WBC count. Filgrastim is a medication that stimulates the production of white blood cells (WBCs).
Therefore, monitoring the WBC count is crucial to evaluate the effectiveness of the treatment. An increase in WBC count indicates that the filgrastim is working to boost the immune system.
Incorrect
Choices:
A: INR - INR measures blood clotting time and is not directly related to the effectiveness of filgrastim.
C: BUN - BUN assesses kidney function, which is not affected by filgrastim.
D: Potassium level - Potassium is not typically affected by filgrastim therapy.
Question 4 of 5
A nurse is caring for a client who has cirrhosis of the liver and is receiving spironolactone. Which of the following findings indicates that the client responding to the treatment?
Correct Answer: B
Rationale: The correct answer is B: Decreased ascites. Spironolactone is a diuretic commonly used to treat fluid retention in patients with cirrhosis. Ascites is the accumulation of fluid in the abdominal cavity, a common complication of liver cirrhosis. Improvement in ascites indicates that the spironolactone is effectively reducing fluid retention. Decreased jaundice (choice
A) is not directly related to spironolactone use. Increased energy (choice
C) and increased appetite (choice
D) are subjective and nonspecific findings that do not directly indicate response to spironolactone in treating ascites.
Question 5 of 5
A nurse is assessing the vital signs of a client who is taking amiodarone. The nurse should anticipate which of the following findings as an adverse effect of the medication?
Correct Answer: B
Rationale: The correct answer is B: Bradycardia. Amiodarone is an antiarrhythmic medication that can cause bradycardia as an adverse effect due to its action on the heart's electrical conduction system. This can lead to a slow heart rate, which the nurse should monitor for. The other choices are incorrect because hypertension (
A) is not a common adverse effect of amiodarone, fever (
C) is not typically associated with this medication, and bradypnea (
D) refers to slow breathing rate, which is not a typical adverse effect of amiodarone.